Microbix Biosystems Inc. (MBX)
Toronto Exchange · Canada · prices in CAD · close of 23 Oct 2026
Key indicators
| Last close | CAD 0.320 |
|---|---|
| 52-week range | 0.210 – 0.325 |
| Return, 1 month / 3 months | +6.7% / +6.7% |
| Return, 1 year / 3 years | +23.1% / +10.3% |
| Trend | Uptrend |
| RSI (14) | 59 |
| Volatility (1 year) | 52.7% |
| Worst drawdown (1 year) | -20.8% |
| Average daily value traded | 0.01M CAD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Microbix Biosystems is a Canadian life sciences company based in Mississauga, Ontario. It produces biological materials used in medical diagnostics, including antigens, antibodies and quality control reagents that laboratories and test manufacturers use to check that their testing systems work correctly. Its customers include diagnostic test makers, clinical laboratories and research organisations that need reliable biological components. The company also develops related biological technologies and products for healthcare and other applications.
The shares are listed on the Toronto Exchange in Canada under the code MBX, and the price on this page is in Canadian dollars (CAD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Microbix Biosystems Inc. (MBX) trades on the Toronto Exchange in Canada. It last closed at CAD 0.320 on 23 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 278 of 870 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 23.1% and over the last three months it rose 6.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Toronto Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 91 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 19.2% | ||
| From 52-week high | 0.0% | ||
| Momentum | 73 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 6.7% | ||
| 6-month return | 30.6% | ||
| 12-month return, skipping the last month | 15.4% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 52.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.8% | ||
| Liquidity | 8 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.01M CAD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +6.7% |
|---|---|
| 1 month | +6.7% |
| 3 months | +6.7% |
| 6 months | +30.6% |
| 1 year | +23.1% |
| 3 years | +10.3% |
| 5 years | −54.3% |
Signals
| 50-day / 200-day average | 0.304 / 0.268 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.009 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Toronto Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.